Sarcopenia is characterised by the progressive loss of skeletal muscle mass and strength during ageing with various adverse outcomes. In our previous study, we found that stage 3 chronic kidney disease (CKD) is strongly associated with sarcopenia. To date, few studies have investigated sarcopenia in non-dialysis CKD patients. So, we studied the prevalence and the factors associated with sarcopenia in mild to moderate CKD. Using data from the Korea National Health and Nutrition Examination Survey (KNHANES) 2008-2010, we included 1,844 men and 2,264 women aged over 55 years. Sarcopenia was defined as an appendicular skeletal muscle mass(kg)/ height(m2)< -1SD for the mean of a younger reference group. As a result, the prevalence of sarcopenia was 30.0% in stage 2, 38.4% in stage 3, and 66.7% in CKD stage 4 in man and 5.2% in stage 2, 4.7% in stage 3, and 12.5% in stage 4 in women. In stage 2 CKD, total hip BMD (β=1.172, p=<0.001), vitamin D (β=0.018, p=<0.001), HOMA-IR (β=-0.028, p=0.001) and amount of protein intake (β=0.001, p=0.008) were associated with skeletal muscle mass in man, and total hip BMD (β=1.761, p=<0.001) and vitamin D (β=0.008, p=<0.001) were associated in women. Meantime, in stage 3, only total hip BMD (β=1.940, p=0.028) was associated with skeletal muscle mass in men, and total hip BMD (β=2.492, p=0.001) and vitamin D (β=0.015, p=0.009) were associated with in women. In conclusions, sarcopenia is prevalent in CKD population, and low BMD and low vitamin D levels are associated with low skeletal muscle mass in mild to moderate CKD patients. Early identification and correction of these factors might help to prevent sarcopenia in CKD patients.
Disclosure: The authors declared no competing interests.